Pharsight

Zolpimist patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236285 AYTU Buccal, polar and non-polar spray containing zolpidem
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7632517 AYTU Buccal, polar and non-polar spray containing zolpidem
Oct, 2017

(6 years ago)

Zolpimist is owned by Aytu.

Zolpimist contains Zolpidem Tartrate.

Zolpimist has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Zolpimist are:

  • US7632517

Zolpimist was authorised for market use on 19 December, 2008.

Zolpimist is available in spray, metered;oral dosage forms.

Zolpimist can be used as treatment of transient insomnia.

The generics of Zolpimist are possible to be released after 07 August, 2032.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 19 December, 2008

Treatment: Treatment of transient insomnia

Dosage: SPRAY, METERED;ORAL

More Information on Dosage

ZOLPIMIST family patents

Family Patents